Table 3

Antimutagenic activity expressed as the mean and standard deviation of number of revertants and percent inhibition by HK of direct (−S9) and indirect (+S9) mutagens, tested on strains TA98, TA100, TA102 and TA 97a of S. typhimurium
Treatments Number of revertants(M ± SD)/ plate and %; of inhibition
HK TA 98 TA 100
μg/plate S9 %; inhibition + S9 %; inhibition S9 %; inhibition + S9 %; inhibition
Ctrol + NOPD B[a]P SA AFB1
638
    +
30
1244
    +
38
1219
    +
46
1607
    +
79
9.7 525
    +
7
18* 874
    +
21
31** 1139
    +
20
7* 1183
    +
30
30**
19.5 507
    +
15
21* 869
    +
4
32** 1112
    +
34
9* 976
    +
18
45***
39.0 477
    +
5
26** 813
    +
18
36** 1169
    +
32
5* 943
    +
11
47***
58.5 521
    +
9
19* 618
    +
6
52*** 1145
    +
16
7* 612
    +
33
71***
78.0 480
    +
16
25** 539
    +
32
59*** 1181
    +
41
3* 354
    +
22
89***
TA 102 TA 97a
μg/plate - S9 %; inhibition + S9 %; inhibition - S9 %; inhibition + S9 %; inhibition
Ctrol + MMC 2-AF NOPD 2-AA
1184
    +
42
1279
    +
12
884
    +
34
1083
    +
67
9.7 1236
    +
17
- 852
    +
21
42*** 934
    +
33
- 682
    +
52
43***
19.5 1201
    +
23
- 855
    +
22
42*** 948
    +
24
- 659
    +
41
45***
39.0 1317
    +
14
- 820
    +
19
46*** 979
    +
84
- 628
    +
16
49***
58.5 1017
    +
56
18* 754
    +
9
52*** 1006
    +
54
- 456
    +
13
67***
78.0 979
    +
51
22* 757
    +
29
52*** 1026
    +
75
- 523
    +
86
60***

HK = (−)-Hinokinin; M ± SD = mean and standard deviation; Ctrol + = positive Control; NOPD = 4 -nitro-o-phenylenediamine (10.0 μg/ plate – TA98 and TA97a); SA = sodium azide (1.25 μg/ plate – TA100); MMC = mitomycin (0.5 μg/ plate – TA102), in the absence of S9 and B[a]P= benzo[a]pyrene (1.0 μg/ plate – TA 98); AFB1 = aflatoxin B1 (0.5 μg/ plate – TA 100); 2-AA = 2-anthramine (1.25 μg/ plate – TA 97a); 2-AF = 2-aminofluorene (10.0 μg/ plate – TA102), in the presence of S9.

* no antimutagenic effect (< 25%; inhibition).

** moderate effect (25%; - 40%; inhibition).

*** strong antimutagenic effect (> 40%; inhibition).

Resende et al.

Resende et al. BMC Complementary and Alternative Medicine 2012 12:203   doi:10.1186/1472-6882-12-203

Open Data